1
|
Neuendorff NR, Boshikova B, Frankenstein L, Kirchner M, Rohde C, Goldschmidt H, Frey N, Müller-Tidow C, Jordan K, Sauer S, Janssen M. Aspirin use and bleeding events during thrombocytopenia after autologous stem-cell transplantation for multiple myeloma. Front Oncol 2023; 13:1168120. [PMID: 37182183 PMCID: PMC10174307 DOI: 10.3389/fonc.2023.1168120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Accepted: 04/06/2023] [Indexed: 05/16/2023] Open
Abstract
Background In patients with cardiovascular (CV) comorbidities that necessitate antiplatelet therapy (APT), its optimal management during chemotherapy-induced thrombocytopenia remains elusive, as the risk of bleeding has to be balanced against the risk of CV events. The purpose of this study was to assess the risk for bleeding with APT during thrombocytopenia in patients with multiple myeloma undergoing high-dose chemotherapy and subsequent autologous stem-cell transplantation (ASCT) with and without acetylsalicylic acid (ASA) as comedication. Methods We assessed patients who underwent ASCT at the Heidelberg University Hospital between 2011 and 2020 for bleeding events, management strategies for ASA intake during thrombocytopenia, transfusion requirements, and the occurrence of CV events. Results There were 57/1,113 patients who continued ASA until at least 1 day after ASCT; thus, a continuous platelet inhibition during thrombocytopenia was assumed. Most of the patients (41/57) continued ASA until they had a platelet count of 20-50/nl. This range reflects the kinetics of thrombocytopenia and nondaily measurements of platelets during ASCT. A tendency toward a higher risk for bleeding events in the ASA group was demonstrated (1.9% (control group) vs. 5.3% (ASA), p = 0.082). The risk factors for bleeding in multivariate analysis were the duration of thrombocytopenia < 50/nl, a history of gastrointestinal bleeding, and diarrhea. The factors predicting the duration of thrombocytopenia were age >60 years, a hematopoietic stem-cell transplantation comorbidity index ≥3, and an impaired bone marrow reserve at admission. CV events occurred in three patients; none of them took ASA or had an indication for APT. Conclusions The intake of ASA until thrombocytopenia with a platelet count of 20-50/nl appears safe, although an elevated risk cannot be excluded. If ASA is indicated for the secondary prevention of CV events, the evaluation of risk factors for bleeding and a prolonged time of thrombocytopenia before conditioning is crucial to adapt the strategy for ASA intake during thrombocytopenia.
Collapse
Affiliation(s)
- Nina Rosa Neuendorff
- Department of Medicine V–Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
- Department of Hematology and Stem-Cell Transplantation, University Hospital Essen, Essen, Germany
| | - Boryana Boshikova
- Department of Medicine V–Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
- Clinic for Cardiology and General Internal Medicine, Städtisches Klinikum Solingen gemeinnützige GmbH, Solingen, Germany
| | - Lutz Frankenstein
- Department of Medicine III–Cardiology, Angiology and Intensive Care, University Hospital Heidelberg, Heidelberg, Germany
| | - Marietta Kirchner
- Institute of Medical Biometry (IMBI), University Hospital Heidelberg, Heidelberg, Germany
| | - Christian Rohde
- Department of Medicine V–Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - Hartmut Goldschmidt
- Department of Medicine V–Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - Norbert Frey
- Department of Medicine III–Cardiology, Angiology and Intensive Care, University Hospital Heidelberg, Heidelberg, Germany
| | - Carsten Müller-Tidow
- Department of Medicine V–Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - Karin Jordan
- Department of Medicine V–Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
- Klinikum Ernst von Bergmann–Department for Hematology, Oncology and Palliative Care, Potsdam, Germany
| | - Sandra Sauer
- Department of Medicine V–Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
| | - Maike Janssen
- Department of Medicine V–Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
- *Correspondence: Maike Janssen,
| |
Collapse
|
2
|
Seeber P, Döbel KU, Isbister JP, Murray K, Shander A, Trentino KM, Lucas M. Mortality and morbidity in non-transfusable and transfusable patients: A systematic review and meta-analysis. Transfusion 2021; 62:685-697. [PMID: 34967018 DOI: 10.1111/trf.16788] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Revised: 11/13/2021] [Accepted: 11/16/2021] [Indexed: 01/28/2023]
Affiliation(s)
- Petra Seeber
- The Institute for Blood Management, Gotha, Germany
| | - Kai-Uwe Döbel
- Department of Anesthesiology, Pain und Palliative Care, Center for Intensive Care, Helios Klinikum Gotha, Gotha, Germany
| | | | - Kevin Murray
- School of Population and Global Health, The University of Western Australia, Perth, Australia
| | - Aryeh Shander
- Department of Anesthesiology and Critical Care, TeamHealth, Englewood Health, Englewood, New Jersey, USA
| | - Kevin M Trentino
- School of Population and Global Health, The University of Western Australia, Perth, Australia
| | | |
Collapse
|
3
|
A single-center experience with head-to-toe microsurgical reconstruction in bloodless medicine patients. J Plast Reconstr Aesthet Surg 2021; 75:823-830. [PMID: 34776392 DOI: 10.1016/j.bjps.2021.08.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 04/21/2021] [Accepted: 08/26/2021] [Indexed: 11/20/2022]
Abstract
Patients who decline blood transfusions, including members of the Jehovah's Witness faith, often face challenges when they require or desire prolonged operations such as free tissue transfer (FTT). This study aims to outline our institution's experience with treating bloodless medicine patients and offers the first anatomically comprehensive evaluation of FTT in this population. All patients undergoing FTT from 2017 to 2020 at a single institution were retrospectively reviewed. Patients who declined blood products were selected. Outcomes of interest include flap success, operative complications, and changes to hemoglobin measurements. Ten patients undergoing 11 FTT procedures were identified. Average age was 62.4 years (SD 7.6). Most patients were female (n = 9) and Black (n = 8). Average body mass index was 31.3 (SD 5.6), American Society of Anesthesiologists Physical Status was 2.9 (SD 0.5), and Charlson Comorbidity Index was 3.8 (SD 1.1). Sites of FTT reconstruction were breast (6), lower extremity (3), and scalp (2). Average operative time was 390 min (SD 85.1), with an average estimated blood loss of 170 mL (SD 100.4). The difference between preoperative hemoglobin to first postoperative hemoglobin measurement averaged 2.2 g/dL (SD 1.4). Average patient follow-up was 12 months (SD 7.8). Flap success occurred in 10 cases. One patient with flap failure was successfully reconstructed with a second procedure. Despite a small, heterogeneous cohort, our success rate in this highly comorbid population indicates that FTT can be performed effectively for patients who cannot use blood products. Bloodless medicine protocols are beneficial to providers serving patients with transfusion restrictions and systems that strive to limit transfusion volume and risk.
Collapse
|
4
|
Jaime-Pérez JC, Hernández-Coronado M, Ancer-Rodríguez J, Gómez-Almaguer D. Increased blood transfusion after outpatient autologous transplantation with reduced intensity conditioning for hematological malignancies predicts worse outcomes. Clin Transplant 2021; 35:e14247. [PMID: 33559181 DOI: 10.1111/ctr.14247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Revised: 01/12/2021] [Accepted: 02/01/2021] [Indexed: 11/28/2022]
Abstract
Transfusion has a recognized immunomodulatory effect, and its role on the outcomes after an ambulatory autologous hematopoietic stem cell transplantation (auto-HSCT) following reduced intensity conditioning (RIC) has not been documented. A study to assess factors associated with the number of packed red blood cells (PRBCs) and platelet units transfused and their impact on survival rates of auto-HSCT recipients after RIC was conducted between 2013 and 2019. Transfusions were recorded from days 0 to 100. Of the 130 patients studied, seventy (53.9%) required transfusion support. The median number of PRBC transfused was 2 (range 1-20), and for platelets, it was also 2 units (range 1-19). Infused CD34 + cells/kg, pre-transplant CMV status, and relapse/progression were significantly associated with the number of PRBC units transfused and sex, infused CD34 + cells/kg, and pre-transplant CMV status with the number of platelet units transfused. In multivariate analysis, a high/very high Disease Risk Index (P = .001) (P = .001) and transfusion of ≥ 5 total blood products (P = .001) (P = .010) were associated with decreased disease-free and overall survival. Two-year cumulative incidence of relapse was 50% for transfused patients vs. 34% for those not transfused (P = .009). These data suggest that the transfusion burden and its interplay with other patient and transplant-related factors could be associated with inferior auto-HSCT outcomes.
Collapse
Affiliation(s)
- José Carlos Jaime-Pérez
- Department of Hematology, Dr. José Eleuterio González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, México
| | - Marcela Hernández-Coronado
- Department of Hematology, Dr. José Eleuterio González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, México
| | - Jesús Ancer-Rodríguez
- Department of Pathology, Facultad de Medicina, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico
| | - David Gómez-Almaguer
- Department of Hematology, Dr. José Eleuterio González University Hospital, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, México
| |
Collapse
|
5
|
Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients. Bone Marrow Transplant 2020; 55:1059-1067. [PMID: 31898692 PMCID: PMC7269908 DOI: 10.1038/s41409-019-0777-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Revised: 11/26/2019] [Accepted: 12/10/2019] [Indexed: 11/25/2022]
Abstract
Due to the curative potential and improvement in progression-free survival (PFS), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered the standard of care for several hematologic malignancies, such as multiple myeloma, and lymphomas. ASCT typically involves support with blood product transfusion. Thus, difficulties arise when Jehovah’s Witness patients refuse blood transfusions. In order to demonstrate the safety of performing “bloodless” ASCT (BL-ASCT), we performed a retrospective analysis of 66 Jehovah's Witnesses patients who underwent BL-ASCT and 1114 non-Jehovah’s Witness patients who underwent transfusion-supported ASCT (TF-ASCT) at Cedars-Sinai Medical Center between January 2000 and September 2018. Survival was compared between the two groups. Transplant-related complications, mortality, engraftment time, length of hospital stay, and number of ICU transfers were characterized for the BL-ASCT group. One year survival was found to be 87.9% for both groups (P = 0.92). In the BL-ASCT group, there was one death prior to the 30 days post transplant due to CNS hemorrhage, and one death prior to 100 days due to sepsis. Based on our data, BL-ASCT can be safely performed with appropriate supportive measures, and we encourage community oncologists to promptly refer JW patients for transplant evaluation when ASCT is indicated.
Collapse
|
6
|
Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, Usmani S, Ford P. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant 2019; 25:e305-e309. [PMID: 31295572 DOI: 10.1016/j.bbmt.2019.07.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Revised: 07/02/2019] [Accepted: 07/03/2019] [Indexed: 11/16/2022]
Abstract
Bloodless autologous hematopoietic cell transplantation is associated with risks of severe bleeding and profound anemia. RBC or platelet transfusions are often used to prevent these hematologic complications. However, in patients such as Jehovah's Witnesses who refuse major blood components, the lack of transfusion support is not an absolute contraindication to an autologous hematopoietic cell transplant. Pennsylvania Hospital performed the world's first bloodless hematopoietic cell transplant more than 15 years ago and has gradually improved its technique with a sizable patient population. Erythropoiesis-stimulating agents were successfully employed as part of their pretransplant regimen to prevent severe anemia. Thrombopoietin agonists' potential role in bloodless transplant is also currently being explored. Although there is limited literature, available reports in combination with physiologic reasoning may support the use of these growth factors to promote transplant success. These agents offer potential benefit and may be of utility in minimizing complications of a bloodless transplant. In this review, we summarize the available literature and offer insight into how we may incorporate growth factors to allow bloodless autologous hematopoietic cell transplantation to be an available option to patients who may otherwise be denied.
Collapse
Affiliation(s)
- Jennifer C Zhao
- Department of Hematology/Oncology, Smilow Cancer Hospital, Yale New Haven Health, New Haven, Connecticut.
| | - Justin R Arnall
- Department of Hematology/Oncology and Bone Marrow Transplantation, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Allison L Martin
- Department of Hematology/Oncology and Bone Marrow Transplantation, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Shebli Atrash
- Department of Hematology/Oncology and Bone Marrow Transplantation, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Manisha Bhutani
- Department of Hematology/Oncology and Bone Marrow Transplantation, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Peter Voorhees
- Department of Hematology/Oncology and Bone Marrow Transplantation, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Belinda Avalos
- Department of Hematology/Oncology and Bone Marrow Transplantation, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Edward Copelan
- Department of Hematology/Oncology and Bone Marrow Transplantation, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Nilanjan Ghosh
- Department of Hematology/Oncology and Bone Marrow Transplantation, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Mehdi Hamadani
- Department of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Saad Usmani
- Department of Hematology/Oncology and Bone Marrow Transplantation, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
| | - Patricia Ford
- Pennsylvania Hospital, Center for Bloodless Medicine and Surgery, Philadelphia, , Pennsylvania
| |
Collapse
|